GlaxoSmithKline Forecast, price target & analysts
GlaxoSmithKline Target price 2026 - Analyst rating & recommendation
GlaxoSmithKline Classifications & Recommendation
GlaxoSmithKline Price Target
| Target Price | £20.40 |
| Price | £18.78 |
| Potential |
8.66%
register free of charge
|
| Number of Estimates | 26 |
|
26 Analysts have issued a price target GlaxoSmithKline 2027 .
The average GlaxoSmithKline target price is £20.40.
This is
8.66%
register free of charge
£31.61
68.34%
register free of charge
£14.70
21.73%
register free of charge
|
|
| A rating was issued by 32 analysts: 14 Analysts recommend GlaxoSmithKline to buy, 15 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the GlaxoSmithKline stock has an average upside potential 2027 of
8.66%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion £ | 32.67 | 34.91 |
| 4.11% | 6.86% | |
| EBITDA Margin | 29.64% | 33.72% |
| 12.33% | 13.75% | |
| Net Margin | 17.50% | 21.49% |
| 113.21% | 22.82% |
26 Analysts have issued a sales forecast GlaxoSmithKline 2026 . The average GlaxoSmithKline sales estimate is
This results in the following potential growth metrics:
20 Analysts have issued an GlaxoSmithKline EBITDA forecast 2026. The average GlaxoSmithKline EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
25 GlaxoSmithKline Analysts have issued a net profit forecast 2026. The average GlaxoSmithKline net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share £ | 1.39 | 1.84 |
| 124.19% | 32.37% | |
| P/E | 10.20 | |
| EV/Sales | 2.61 |
25 Analysts have issued a GlaxoSmithKline forecast for earnings per share. The average GlaxoSmithKline EPS is
This results in the following potential growth metrics and future valuations:
GlaxoSmithKline...
Current GlaxoSmithKline Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Deutsche |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | May 28 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | May 27 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Citigroup |
Locked
➜
Locked
|
Locked | May 06 2026 |
| Deutsche |
Locked
➜
Locked
|
Locked | Apr 28 2026 |
| Jefferies |
Locked
➜
Locked
|
Locked | Apr 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Deutsche:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
May 27 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
May 06 2026 |
|
Locked
Citigroup:
Locked
➜
Locked
|
May 06 2026 |
|
Locked
Deutsche:
Locked
➜
Locked
|
Apr 28 2026 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Apr 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
